Literature DB >> 32336230

Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy.

Aaron L Sverdlov1,2, Nicholas J Collins1,2, Mohammed S Al-Omary1,2, Stuart Sugito1, Andrew J Boyle1,2.   

Abstract

Pulmonary hypertension (PH) due to left heart disease (LHD) is the most common type of PH and is defined as mean pulmonary artery systolic pressure of >20 mm Hg and pulmonary capillary wedge pressure >15 mm Hg during right heart catheterization. LHD may lead to elevated left atrial pressure alone, which in the absence of intrinsic pulmonary vascular disease will result in PH without changes in pulmonary vascular resistance. Persistent elevation in left atrial pressure may, however, also be associated with subsequent pulmonary vascular remodeling, vasoconstriction, and an increase in pulmonary vascular resistance. Hence, there are 2 subgroups of PH due to LHD, isolated postcapillary PH and combined post- and precapillary PH, with these groups have differing clinical implications. Differentiation of pulmonary arterial hypertension and PH due to LHD is critical to guide management planning; however, this may be challenging. Older patients, patients with metabolic syndrome, and patients with imaging and clinical features consistent with left ventricular dysfunction are suggestive of LHD etiology rather than pulmonary arterial hypertension. Hemodynamic measures such as diastolic pressure gradient, transpulmonary gradient, and pulmonary vascular resistance may assist to differentiate pre- from postcapillary PH and offer prognostic insights. However, these are influenced by fluid status and heart failure treatment. Pulmonary arterial hypertension therapies have been trialed in the treatment with concerning results reflecting disease heterogeneity, variation in inclusion criteria, and mixed end point criteria. The aim of this review is to provide an updated definition, discuss possible pathophysiology, clinical aspects, and the available treatment options for PH due to LHD.

Entities:  

Keywords:  cardiac catheterization; heart failure; hypertension, pulmonary; pulmonary wedge pressure; vascular remodeling

Mesh:

Year:  2020        PMID: 32336230     DOI: 10.1161/HYPERTENSIONAHA.119.14330

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

Review 1.  Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure.

Authors:  Jason Stencel; Indranee Rajapreyar; Rohan Samson; Thierry Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2022-09-01

2.  Decreased Peak Left Atrial Longitudinal Strain Is Associated with Persistent Pulmonary Hypertension Associated with Left Heart Disease.

Authors:  Ju-Hee Lee; Jae-Hyeong Park; In-Chang Hwang; Jin Joo Park; Jun-Bean Park
Journal:  J Clin Med       Date:  2022-06-18       Impact factor: 4.964

3.  The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.

Authors:  Ying Zhao; Li-Guo Tian; Li-Xin Zhang; Tao Ma; Liang Di; Yan-Bo Wang; Xin-Shun Gu; Dan-Dan Wang; Shang Gao; Haiyan Wang
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

4.  Prevalence and survival associated with pulmonary hypertension after mitral valve replacement: National echocardiography database of Australia study.

Authors:  Nicholas Collins; Stuart Sugito; Allan Davies; Andrew Boyle; Aaron Sverdlov; John Attia; Simon Stewart; David Playford; Geoff Strange
Journal:  Pulm Circ       Date:  2022-10-01       Impact factor: 2.886

Review 5.  Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.

Authors:  Filippos Triposkiadis; Andrew Xanthopoulos; John Skoularigis; Randall C Starling
Journal:  Heart Fail Rev       Date:  2022-04-18       Impact factor: 4.654

Review 6.  Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension.

Authors:  Adrija Hajra; Israel Safiriyu; Prasanth Balasubramanian; Rahul Gupta; Selia Chowdhury; Abhishek J Prasad; Akshay Kumar; Deepak Kumar; Baseer Khan; Roberta S F Bilberry; Ankit Sarkar; Paras Malik; Wilbert S Aronow
Journal:  Curr Probl Cardiol       Date:  2022-04-29       Impact factor: 16.464

7.  Pulmonary vascular distensibility with passive leg raise is comparable to exercise and predictive of clinical outcomes in pulmonary hypertension.

Authors:  Callyn J Kozitza; Naga Dharmavaram; Ran Tao; Diana M Tabima; Naomi C Chesler; Farhan Raza
Journal:  Pulm Circ       Date:  2022-01-12       Impact factor: 2.886

8.  Pulmonary Hypertension as a Predictor of Early Outcomes of Mitral Valve Replacement: A Study in Rheumatic Heart Disease Patients.

Authors:  Omer Farooq; Azam Jan; Usman Ghani; Usman Qazi; Waasay Hassan Khan; Sundus Alam; Muhammad Junaid Khan; Omair A Khan; Nabil I Awan; Hussain Shah
Journal:  Cureus       Date:  2021-12-01

9.  Peak oxygen uptake is a strong prognostic predictor for pulmonary hypertension due to left heart disease.

Authors:  Xiu-Jun Zhong; Rong Jiang; Lu Yang; Ping Yuan; Su-Gang Gong; Qin-Hua Zhao; Ci-Jun Luo; Hong-Ling Qiu; Hui-Ting Li; Rui Zhang; Jing He; Lan Wang; Jie Tang; Jin-Ming Liu
Journal:  BMC Cardiovasc Disord       Date:  2022-03-31       Impact factor: 2.298

10.  Pregnant outcomes of critically ill pregnant patients with pulmonary hypertension: A multicenter retrospective study.

Authors:  Lin Zhang; Guoqiang Qie; Xiaoyu Yin; Hongyan Zhao; Fusen Zhang; Tao Wang; Mei Meng; Jing Sha; Yufeng Chu
Journal:  Front Cardiovasc Med       Date:  2022-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.